CytoDyn Gets Greenlight from Its Investigators for China Joint Venture.

SANTA FE, N.M. -- CytoDyn, Inc. (OTCBB:CYDY) has been advised by its investigators in the United States and Hong Kong that there is no derogatory information that would preclude the Company from joining with Timeway International for a joint venture in China. The anticipated joint venture would develop Cytolin(R), CytoDyn's targeted immune therapy for HIV/AIDS, in that populous Asian nation. UNAIS and other organizations have estimated that by 2010 there could be a generalized HIV epidemic in China with between 10 and 20 million Chinese infected. (Source: "Averting a Full-Blown HIV/AIDS Epidemic in China" - A report of the CSIS HIV/AIDS Delegation to China, January 13-17. 2003.)

Cytolin(R) is the first targeted immune therapy for HIV/AIDS that was shown to significantly reduce viral burden in preliminary human studies. The potential advantage is that Cytolin(R) exerts its effect on the immune system and not the virus. As a result, a species of virus resistant to the effects of Cytolin(R) cannot emerge through natural selection because the drug has no effects on the virus itself.

In addition to providing an additional treatment for the disease, Cytolin(R) might extend the useful life of the antiretroviral drugs currently used to treat HIV/AIDS, such as Emtriva(R) and Truvada(R) manufactured by Gilead (Nasdaq:GILD), Epzicom(R) and Lexiva(R) manufactured by GlaxoSmithKline (NYSE:GSK), and Reyataz(R) and Zerit(R) manufactured by Bristol-Myers Squibb (NYSE:BMY). If, for instance, random mutation in an infected host produced a species of HIV that was resistant to the protease inhibitors, then the host's immune system might suppress that species if Cytolin(R) were used as an adjunctive therapy. If so, then the host would not wind up being colonized by a species of virus resistant to the protease inhibitors.

Both potential roles for Cytolin(R) could be important in China. The 'Four Frees and One Care Policy,' which the Chinese Government began implementing in 2004, includes providing free anti-HIV drugs to AIDS patients who are rural residents. But the ability to keep regimens of Highly Active Antiretroviral Therapy (HAART) up to date could be inhibited by the mobility of China's migrant population, estimated to be as high as 120 million people. (Source: www.avert.org/aidshina.htm).

Huey Hua ([e-mail]), a Chinese-speaking consultant to CytoDyn, will represent the Company in the Asian Markets and plans on traveling to China in the near future to meet with Philip Liu, Timeway's President.